<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
[X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934 for the quarterly period ended September 30, 1997, or
[ ] Transition Period Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934 for the Transition Period From __ to __.
Commission file number 0-19591
CYTEL CORPORATION
(Exact name of Registrant as specified in its charter)
Delaware 33-0245076
3525 John Hopkins Court
San Diego, California 92121
(Address of principal executive offices)
(619) 552-3000
(Registrant's telephone number)
Indicate by check mark whether the Registrant (1) has filed all reports to be
filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the Registrant was required
to file such reports), and (2) has been subject to such filing requirements for
the past 90 days.
Yes X No __
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.
Common Stock: $.01 par value, 27,214,886 shares outstanding as of September
30, 1997
<PAGE> 2
CYTEL CORPORATION
TABLE OF CONTENTS
<TABLE>
<CAPTION>
PAGE
----
<S> <C> <C>
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
Condensed Consolidated Balance Sheets as of
September 30, 1997 and December 31, 1996..................1
Condensed Consolidated Statements of Operations
for the Three and Nine Months Ended
September 30, 1997 and 1996...............................2
Condensed Consolidated Statements of Cash Flows
for the Nine Months Ended September 30, 1997 and 1996.....3
Notes to Condensed Consolidated Financial Statements......4
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations.......................6
PART II. OTHER INFORMATION
Items 1 to 6......................................................10
Signatures........................................................11
</TABLE>
<PAGE> 3
PART I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
CYTEL CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
<TABLE>
<CAPTION>
September 30, December 31,
1997 1996
------------- -------------
(Unaudited) (Note)
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents $ 4,832,000 $ 3,231,000
Short-term investments 10,229,000 20,645,000
Current portion of restricted cash 375,000 375,000
Prepaids and other current assets 1,325,000 1,422,000
------------- -------------
Total current assets 16,761,000 25,673,000
Restricted cash 750,000 1,031,000
Property and equipment, net 1,561,000 2,935,000
Deposits and other assets 6,061,000 4,651,000
------------- -------------
Total assets $ 25,133,000 $ 34,290,000
============= =============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued liabilities $ 1,332,000 $ 1,991,000
Deferred contract revenues 574,000 732,000
Accrued payroll and related expenses 390,000 650,000
Line of credit 375,000 375,000
Current portion of obligations under capital leases and equipment notes payable 81,000 341,000
------------- -------------
Total current liabilities 2,752,000 4,089,000
Deferred rent payable 1,463,000 1,640,000
Equipment notes payable -- 40,000
Line of credit 750,000 1,031,000
Stockholders' equity:
Preferred stock, $.01 par value, 10,000,000 shares
authorized, none issued or outstanding -- --
Common stock, $.01 par value, 50,000,000 shares
authorized, 27,214,886 and 25,091,309 shares issued and
outstanding at September 30, 1997 and December 31, 1996, respectively 272,000 251,000
Additional paid-in capital 123,119,000 120,095,000
Accumulated deficit (103,178,000) (92,792,000)
Unrealized losses on available-for-sale securities (45,000) (64,000)
------------- -------------
Total stockholders' equity 20,168,000 27,490,000
------------- -------------
Total liabilities and stockholders' equity $ 25,133,000 $ 34,290,000
============= =============
</TABLE>
Note: The balance sheet at December 31, 1996 has been derived from the audited
consolidated financial statements at that date but does not include all of the
information and footnotes required by generally accepted accounting principles
for complete financial statements.
See notes to condensed consolidated financial statements.
1
<PAGE> 4
PART I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
CYTEL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
<TABLE>
<CAPTION>
Three months ended September 30, Nine months ended September 30,
--------------------------------- ---------------------------------
1997 1996 1997 1996
------------ ------------ ------------ ------------
(Unaudited) (Unaudited)
<S> <C> <C> <C> <C>
REVENUES
Research and development $ 1,625,000 $ 1,611,000 $ 2,750,000 $ 6,031,000
Research grants and other income 196,000 574,000 1,131,000 1,701,000
------------ ------------ ------------ ------------
1,821,000 2,185,000 3,881,000 7,732,000
OPERATING EXPENSES
Research and development 3,807,000 4,568,000 12,305,000 16,032,000
General and administrative 950,000 906,000 2,577,000 2,661,000
------------ ------------ ------------ ------------
4,757,000 5,474,000 14,882,000 18,693,000
Interest income, net 169,000 323,000 615,000 1,160,000
------------ ------------ ------------ ------------
Net loss $ (2,767,000) $ (2,966,000) $(10,386,000) $ (9,801,000)
============ ============ ============ ============
Net loss per share $ (0.11) $ (0.12) $ (0.41) $ (0.40)
============ ============ ============ ============
Shares used in computing net loss per share 25,445,269 24,893,972 25,228,790 24,795,598
============ ============ ============ ============
</TABLE>
See notes to condensed consolidated financial statements.
2
<PAGE> 5
PART I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
CYTEL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
<TABLE>
<CAPTION>
Nine months ended September 30,
---------------------------------
1997 1996
------------ ------------
(Unaudited)
<S> <C> <C>
OPERATING ACTIVITIES
Net loss $(10,386,000) $ (9,801,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization 664,000 1,163,000
Deferred rent (177,000) (144,000)
Amortization of deferred compensation -- 140,000
Deferred revenue (158,000) (2,135,000)
Gain on sale of equipment (35,000) --
Changes in operating assets and liabilities:
Receivable under collaborative agreement -- 2,000,000
Other current assets 97,000 (271,000)
Accounts payable and accrued liabilities (659,000) 569,000
Accrued payroll and related expenses (260,000) (81,000)
------------ ------------
Net cash used in operating activities (10,914,000) (8,560,000)
INVESTING ACTIVITIES
Purchases of available-for-sale securities (23,923,000) (91,712,000)
Maturities of available-for-sale securities 17,764,000 57,332,000
Sales of available-for-sale securities 16,594,000 44,093,000
Proceeds from the sale of equipment 35,000 --
Proceeds from the sale of assets of subsidiary 211,000 --
Property and equipment (240,000) (1,603,000)
Deposits and other assets (671,000) (679,000)
------------ ------------
Net cash provided by investing activities 9,770,000 7,431,000
FINANCING ACTIVITIES
Principal payments under capital lease obligations and equipment notes payable (300,000) (663,000)
Principal payments under line of credit obligations (281,000) --
Restricted cash for line of credit collateral 281,000 --
Net proceeds from issuance of common stock 3,045,000 1,337,000
------------ ------------
Net cash provided by investing activities 2,745,000 674,000
Increase (decrease) in cash and cash equivalents 1,601,000 (455,000)
Cash and cash equivalents at beginning of period 3,231,000 10,543,000
------------ ------------
Cash and cash equivalents at end of period $ 4,832,000 $ 10,088,000
============ ============
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Interest paid $ 95,000 $ 166,000
============ ============
SUPPLEMENTAL DISCLOSURES OF NONCASH INVESTING AND
FINANCING ACTIVITIES
Unrealized gains (losses) on available-for-sale securities $ 19,000 $ (169,000)
============ ============
Promissory note and stock received for sale of assets of subsidiary $ 800,000 $ --
============ ============
</TABLE>
See notes to condensed consolidated financial statements.
3
<PAGE> 6
PART 1. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
CYTEL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
1. Basis of Presentation
The interim unaudited condensed consolidated financial statements contained
herein have been prepared in accordance with generally accepted accounting
principles for interim financial information. Accordingly, they do not include
all of the information and footnotes required by generally accepted accounting
principles for complete financial statements. In management's opinion, the
unaudited information includes all adjustments, consisting only of normal
recurring accruals, necessary for a fair presentation of the financial position,
results of operations and cash flows for the periods presented. Interim results
are not necessarily indicative of results to be expected for the full year. The
financial statements should be read in conjunction with the audited consolidated
financial statements and footnotes thereto included in the Registrant's Form
10-K for the year ended December 31, 1996.
The condensed consolidated financial statements include the accounts of
Cytel Corporation and its subsidiaries ("Cytel" or the "Company"). All
significant intercompany accounts and transactions have been eliminated.
Net loss per share is computed using the weighted average number of common
shares outstanding during the period. In February 1997, the Financial Accounting
Standards Board (FASB) issued Statement of Financial Accounting Standards No.
128, Earnings per Share, which supersedes APB Opinion No. 15. Statement No. 128
replaces the presentation of primary Earnings per Share (EPS) with "Basic EPS"
which includes no dilution and is based on weighted-average common shares
outstanding for the period. Companies with complex capital structures will also
be required to present "Diluted EPS" that reflects the potential dilution of
securities like employee stock options. Statement No. 128 is effective for
financial statements issued for periods ending after December 15, 1997. The
impact of Statement No. 128 will not be material to the consolidated financial
statements of the Company.
2. Research and Development Agreements
In September 1997, the Company signed a letter of intent with G.D. Searle
("Searle") to collaborate to develop new cancer therapies through its
newly-formed subsidiary, Epimmune Inc. ("Epimmune"). As part of the agreement,
Searle made a $5 million investment in Cytel common stock.
In September 1996, the Company entered into a collaborative agreement with
Baxter Healthcare Corporation's Nextran unit ("Nextran") to develop a
carbohydrate product for use in xenotransplantation. Under the agreement, the
Company will manufacture and sell a carbohydrate which Nextran will incorporate
into a xenotransplant product. Nextran made an up-front payment of $500,000 and
purchased 158,228 shares of the Company's common stock at $6.32 per share for
the right to enter into an exclusive supply agreement. Nextran will make
additional payments to
4
<PAGE> 7
PART 1. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
the Company upon option exercise, achievement of milestones and supply of
carbohydrate. In January 1997, the Company achieved a milestone with delivery of
the initial batch of a bioactive carbohydrate to Nextran. As a result, Nextran
made the first milestone payment in the amount of $500,000.
In December 1995, the Company entered into a collaborative agreement with
Abbott Laboratories ("Abbott") to develop manufacturing processes for the
production of certain carbohydrates for use in nutritional products. Abbott paid
a $2 million up-front fee in January 1996 for an option to obtain a worldwide
license for limited applications under the Company's patents and know-how in the
area of carbohydrate synthesis. Abbott will make milestone payments to the
Company upon achievement of production and commercial milestones and will pay
royalties on the volume of product sold. In December 1996, Abbott made the first
milestone payment to the Company in the amount of $2 million.
In May 1995, the Company entered into a collaborative agreement with
Schwarz Pharma AG ("Schwarz") for the development and marketing of carbohydrate
selectin blockers, including Cylexin. Under the terms of the agreement, Schwarz
made an up-front license payment and purchased 241,546 shares of the Company's
common stock at $8.28 per share. Schwarz funded 75% of clinical development
costs associated with the Phase II acute myocardial infarction trial from 1995
until termination of the agreement. In December 1995, Schwarz made the first
milestone payment to the Company in the form of the purchase of an additional
241,546 shares of the Company's common stock at $8.28 per share. In April 1997,
the Company and Schwarz agreed to terminate their collaboration.
Under two agreements with Takara Shuzo Co., Ltd. Biomedical Group
("Takara"), the Company's Theradigm technology is being applied to fungal
disease targets and cellular therapy for the treatment of cancer. Under the
anti-fungal collaboration initiated in June 1994, Takara obtained rights to any
anti-fungal products resulting from the collaboration for commercialization in
Japan. The Company has the right to develop products in North America, and the
companies share rights in the rest of the world. As part of the anti-fungal
collaboration, Takara supported research at the Company for 18 months, and in
September 1994, purchased 400,000 shares of the Company's common stock at $7.50
per share. Research in the anti-fungal field, using Cytel technology, is now
being conducted independently by Takara in Japan. Under the cellular therapy
collaboration initiated in October 1994, Takara obtained rights to the Company's
technology relevant to the development of ex vivo cellular therapies for the
treatment of cancer in Japan. The Company retains all rights to ex vivo cellular
therapy outside Japan. Takara will pay royalties on sales from products
resulting from collaboration under both agreements.
In October 1991, the Company entered into a five-year collaborative
agreement with Sumitomo Pharmaceuticals Co., Ltd. ("Sumitomo") to develop drugs
based on the Company's technology for the treatment of white blood cell-mediated
diseases. Under the terms of the agreement, Sumitomo provided research support
payments of $15 million. In October 1996, the agreement was extended for three
months and Sumitomo paid $375,000. In January 1997, the collaborative research
agreement expired. Sumitomo has certain rights and obligations with respect to
development of compounds which resulted from the collaboration for Pacific Rim
markets. Sumitomo is obligated to make payments if certain milestones are met
and pay royalties to the Company on sales of such products. Total option fees
and milestone payments will not exceed $25 million. The Company has retained
worldwide manufacturing rights and all rights to sell drugs resulting from the
collaboration in the United States and other markets.
5
<PAGE> 8
PART 1. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
In October 1994, Sumitomo completed its equity investment in the Company
with the purchase of 1,408,450 shares of the Company's common stock at $3.55 per
share. In October 1992 and December 1994, Sumitomo exercised its option to
license candidate compounds and made milestone payments of $0.5 million and $1.0
million, respectively. In 1995, Sumitomo exercised its option on all additional
compounds to be generated within the collaboration and made an additional
milestone payment of $1.0 million.
PART 1. FINANCIAL INFORMATION
ITEM 2. MANAGEMENT'S DISCUSSION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Except for the historical information contained herein, the following
discussion contains forward-looking statements that involve risks and
uncertainties. The Company's actual results could differ materially from those
discussed here. Factors that could cause or contribute to such differences
include, without limitation, those discussed in this section and those discussed
in the Company's Annual Report on Form 10-K for the fiscal year ended December
31, 1996.
Since its inception in July 1987, Cytel has devoted substantially all of
its resources to the discovery and development of its potential
immunotherapeutic products and development of its proprietary carbohydrate
manufacturing technology. To date, Cytel has not received any revenues from the
sale of products. The Company has funded its research and development primarily
from equity-derived working capital and through strategic alliances with other
companies. The Company has been unprofitable since its inception and expects to
incur substantial operating losses for the next several years. As of September
30, 1997, the Company's accumulated deficit was $103.2 million.
RESULTS OF OPERATIONS
Revenues for the three and nine months ended September 30, 1997 were $1.8
million and $3.9 million as compared to $2.2 million and $7.7 million,
respectively, for the same periods in 1996. The Company earned research and
development revenues in the third quarter of 1997 from Abbott and from the $5
million sale of equity at a premium over market to Searle pursuant to the letter
of intent between Searle and Cytel. Revenues in the third quarter of 1996
included development funding from a collaboration agreement with Schwarz, as
well as research support from Sumitomo. Due to the expiration and termination of
the collaboration agreements with Sumitomo and Schwarz, respectively, in January
and April of 1997, there are substantially lower research and development
revenues from existing collaborations in 1997 as compared to 1996. Additional
research and development revenues for 1997 are dependent upon the achievement of
milestones under existing collaboration agreements with Abbott and Nextran, the
achievement of milestones by Sumitomo under the license agreement with Sumitomo,
or the initiation of new collaborative research and development, supply or
licensing relationships. There can be no assurance that the Company will be able
to establish or maintain any such relationships. Research grant revenues for the
three and nine months ended September 30, 1997 decreased from the comparable
periods in 1996 due to a lesser number of active grants in 1997 as compared to
6
<PAGE> 9
PART 1. FINANCIAL INFORMATION
ITEM 2. MANAGEMENT'S DISCUSSION
1996. Three additional grants expired during the second and third quarters of
1997. Total grant revenue for 1997 will be lower than 1996 but offset by the
award of two new research grants effective for the fourth quarter of 1997.
Research and development expenses for the three and nine month periods
ended September 30, 1997 decreased by $0.8 million and $3.7 million from the
same periods in 1996. The decreases reflect lower costs associated with the
Company's ongoing clinical program for Cylexin, lower costs associated with the
Company's Theradigm-HBV clinical program which has been completed, as well as
reduced expenditures for manufacturing supplies and lower depreciation expense.
In January 1997, the Company sold certain assets of Receptor Laboratories,
Inc. ("RLI"), a wholly-owned subsidiary, for aggregate consideration valued at
approximately $950,000. The sale of RLI represents cost savings of approximately
$200,000 per quarter of research and development expenses and reduced
depreciation expense, for an expected annual cost savings of approximately
$800,000 for 1997 as compared to 1996.
General and administrative expenses increased slightly for the three months
ended September 30, 1997 as compared to the three months in 1996 and decreased
slightly for the nine month period ended September 30, 1997 compared to the same
period in 1996.
Net interest income decreased $0.2 million and $0.5 million for the three
and nine month periods ended September 30, 1997 as compared to the same periods
in 1996. Lower interest income is primarily attributable to lower average cash
balances in 1997.
During April 1997, the Company announced the restructuring of operations
and the spin out of its vaccine program to form a new company, Epimmune Inc. The
formation of Epimmune, as a wholly-owned subsidiary was completed in October
1997. The Company invested approximately $6.5 million in cash and $1.5 million
of the assets relating to the vaccine technology program. This transaction
followed the $5 million investment by Searle in September 1997 to purchase Cytel
common stock pursuant to the letter of intent between the Company and Searle to
establish a collaboration focused on developing a new class of cancer therapies.
Cytel will focus on building its Glytec carbohydrate manufacturing business and
on the discovery, development and commercialization of therapeutics for
inflammatory diseases including Cylexin.
The Company expects to incur substantial operating losses over the next
several years due to continuing expenses associated with its research and
development programs, including preclinical testing and clinical trials.
Operating losses may fluctuate from quarter to quarter as a result of
differences in the timing of revenues and expenses, and such fluctuations may be
substantial.
LIQUIDITY AND CAPITAL RESOURCES
The Company had net working capital of $14.0 million at September 30, 1997
compared to $21.6 million at December 31, 1996. Cash, cash equivalents,
short-term investments and restricted cash decreased to $16.2 million at
September 30, 1997 as compared to $25.3 million at December 31, 1996. For the
three months ended September 30, 1997, cash, cash equivalents, short-term
investments and restricted cash increased by $0.7 million due to the $5
7
<PAGE> 10
PART 1. INFORMATION
ITEM 2. MANAGEMENT'S DISCUSSION
million investment by Searle offset by third quarter operating losses. Net cash
used in operating activities was $10.9 million and $8.6 million, respectively,
for the nine months ended September 30, 1997 and 1996. The increase in net cash
used in operating activities was due primarily to lower revenues in 1997 as
compared to the prior year and the pay down of current liabilities in 1997
versus the net increase in accounts payable and accrued liabilities for the same
period in 1996. For the nine months ended September 30, 1997, the Company
acquired an aggregate of $0.2 million in capital equipment compared to $1.6
million for the same period in 1996.
The Company has invested $6.5 million of cash to fund Epimmune's
operations following the equity investment by Searle of $5 million to purchase
Cytel common stock. The Company plans no further investments in Epimmune.
The Company's cash, cash equivalents and short-term investments are
expected to decline primarily due to the continued clinical development of
Cylexin and the conduct of its research programs. While the Company's
investments may periodically reflect unrealized losses, management attempts to
schedule the maturities of the Company's investments to coincide with the
Company's expected cash requirements.
The Company expects to incur substantial additional research and
development expenditures, including costs related to preclinical testing,
clinical trials and manufacturing. It is the Company's intention to seek
additional collaborative research and development relationships with suitable
corporate partners. There can be no assurance that any agreements that may
result from these discussions will successfully reduce the Company's funding
requirements. Additional equity or debt financing will be required, and there
can be no assurance that these funds will be available on favorable terms, if at
all. If adequate funds are not available, the Company may be required to delay,
scale back or eliminate one or more of its drug discovery or development
programs or obtain funds through arrangements with collaborative partners or
others that may require the Company to relinquish rights to certain of its
technologies, product candidates or products that the Company would not
otherwise relinquish.
If additional financing is not available, Cytel anticipates its existing
available cash, cash equivalents and short-term investments, investment income
and research and development funding from collaborative agreements and research
grants will be adequate to satisfy its capital requirements and fund operating
losses through at least the middle of 1998. The Company's future capital
requirements depend on many factors, including the ability of the Company to
establish and maintain collaborative arrangements, particularly with respect to
commercial application of the Company's carbohydrate manufacturing technology,
progress with preclinical testing and clinical trials, the time and costs
involved in obtaining regulatory approvals, the costs involved in filing,
prosecuting and enforcing patent claims, competing technological and market
developments, changes in the existing collaborative research relationships, the
ability of the Company to establish and maintain development arrangements,
continued scientific progress in its drug discovery programs, the magnitude of
these programs, the cost of manufacturing scale-up and effective
commercialization activities and arrangements.
As is typical in the biotechnology industry, the commercial success of the
Company will depend in part on the Company neither infringing patents issued to
competitors nor breaching the technology licenses upon which the Company's
products might be based. The Company is aware of third party patent applications
and issued patents that may require the Company to alter products or processes,
obtain licenses or cease certain activities. Based on preliminary investigation,
the Company believes that its compound, Cylexin, which is currently in Phase II
clinical trials for infants undergoing surgery to correct congenital heart
defect, may infringe one or more claims of a patent issued to a third party. The
Company is continuing to investigate the validity and scope of
8
<PAGE> 11
PART 1. FINANCIAL
ITEM 2. MANAGEMENT'S DISCUSSION
the patent. Subject to this further investigation, the Company believes that it
may be required to either obtain a license from the third party in order to
manufacture and market Cylexin or, alternatively, to shift its development
effort to another compound with attendant delay. There can be no assurance the
Company will be able to obtain any necessary license at a reasonable cost.
Failure by the Company to obtain a license to any technology that it requires to
commercialize its products, or to develop an alternative compound and obtain FDA
approval within an acceptable period of time if required to do so, would have a
material adverse effect on the Company.
The Company's business is also subject to other significant risks,
including the uncertainties associated with the lengthy regulatory approval
process and with potential competition from other products. Even if the
Company's products appear promising at an early stage of development, they may
not reach the market for a number of reasons. Such reasons include, but are not
limited to, the possibilities that the potential products will be found
ineffective during clinical trials, fail to receive necessary regulatory
approvals, be difficult to manufacture on a large scale, or be uneconomical to
market.
The timing and activities contemplated by the proposed restructuring of the
Company may differ significantly from those discussed in the forward-looking
statements due to a variety of legal, tax and operational uncertainties,
including risks associated with creating and financing new companies.
9
<PAGE> 12
PART II. OTHER INFORMATION
1. Legal Proceedings
The Company is not a party to any legal proceedings.
2. Change in Securities
On September 18, 1997, the Company issued an aggregate of 2,000,000 shares
of Common Stock to G.D. Searle & Co. in connection with the signing of a
letter of intent to collaborate to develop new cancer therapies through the
Company's wholly-owned subsidiary, Epimmune Inc. The Company received
aggregate consideration of $5,000,000 in cash as payment for the shares.
The shares were issued in a transaction exempt from registration under
Section 4(2) of the Securities Act of 1933 as amended.
3. Defaults Upon Senior Securities
None.
4. Submission of Matters to a Vote of Security Holders
None.
5. Other Information
None.
6. Exhibits and Reports on Form 8-K
(a) Exhibits.
Exhibit 10.52 Letter of Intent, between the Registrant and G.D.
Searle & Co., dated September 5, 1997 (with certain confidential
portions deleted). (1)
Exhibit 10.53 Stock Purchase Agreement, between the Registrant and
G.D. Searle & Co., dated September 18, 1997.
Exhibit 27. Financial Data Schedule
(1) Certain confidential portions deleted subject to the Application
for Confidential Treatment pursuant to Rule 24b-2 under the
Securities Exchange Act of 1934 filed by the Registrant with the
Commission concurrently herewith.
(b) Reports on Form 8-K.
None.
10
<PAGE> 13
CYTEL CORPORATION
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
CYTEL CORPORATION
Date: November 14, 1997 By: /s/ Virgil Thompson
--------------------------------
Virgil Thompson
President and Chief Executive
Officer, and Chief Financial Officer
(Duly Authorized Officer and
Principal Financial Officer)
Date: November 14, 1997 By: /s/ Paula Moody
--------------------------------
Paula Moody
Controller
(Principal Accounting Officer)
11
<PAGE> 1
Exhibit 10.52
Searle
Box 5110
Chicago, Illinois 60680-5110
Telephone 847 982 7000
Fax 847 470 1480
September 5, 1997 CONFIDENTIAL
Cytel Corporation
3525 John Hopkins Court
San Diego, CA 92121
Attention: Virgil D. Thompson
President and CEO
Gentlemen and Ladies:
G.D. Searle & Co. ("Searle"), a wholly-owned subsidiary of Monsanto Company
("Monsanto"), is pleased to submit an offer to enter into and complete a
transaction which would result in an equity investment in Cytel Corporation
("Cytel") and in certain licensing and other collaborative activities, all as
more particularly described herein. Searle is extremely interested in
establishing a collaborative alliance with Cytel to maximize its technology in
the cancer treatment area and believes our offer demonstrates our commitment to
do so.
I. OFFER. SUBJECT TO THE CONDITIONS CONTAINED IN THIS OFFER LETTER, SEARLE
OFFERS TO MAKE AN EQUITY INVESTMENT IN CYTEL IN THE TOTAL AMOUNT OF ***
IN THREE (3) PHASES, THE DETAILS OF WHICH ARE DESCRIBED BELOW. IN
CONSIDERATION FOR SUCH *** SEARLE WILL RECEIVE AN EQUITY POSITION IN
CYTEL AND CERTAIN LICENSE RIGHTS TO CYTEL TECHNOLOGY AS DESCRIBED UNDER
PHASE I AND PHASE II BELOW. UPON CYTEL'S ACCEPTANCE OF THE CONDITIONS
CONTAINED IN THIS OFFER LETTER, SEARLE IS PREPARED TO IMPLEMENT PHASE I.
A. Phase I
1. Equity Investment. Within seven (7) business days after Cytel's
acceptance of this offer, Searle will purchase shares of common
stock of Cytel from Cytel at a purchase price equal to $2.50 per
share, *** as part of the current private placement or, if such
private placement is terminated for whatever reason or completed
at a price lower than $2.00 per share, the number of shares
purchased by Searle shall be increased so that the average
purchase price of the shares is the higher of $2.25 or $0.50
above the private placement price for an aggregate purchase
price of five million
CONFIDENTIAL TREATMENT REQUESTED
<PAGE> 2
Cytel Corporation
September 5, 1997
Page 2
dollars ($5,000,000) provided (a) *** of the issued and
outstanding shares of common stock of Cytel on the date of
purchase by Searle, (b) Cytel shall use the proceeds of the sale
of the shares for the purpose of funding its Epimmune(TM) unit,
and (c) Cytel indicates in writing its agreement to the
provisions of this Section I.A. and to the concepts contained in
the remainder of this offer letter which shall be incorporated
into definitive agreements to be negotiated in good faith by
Cytel and Searle during the Exclusivity Period (defined in
paragraph I.A.3). The shares will be purchased by Searle in
accordance with the terms and conditions of a Stock Purchase
Agreement substantially in the form of Exhibit A attached
hereto. The parties acknowledge that any sale by Searle of Cytel
common stock will be pursuant to Rule 144 of the Securities Act
of 1983.
2. License Rights.
(a) Cytel will grant to Searle under the definitive agreements
*** to make, have made, use and sell pharmaceutical
products derived from Cytel's cancer epitopes and *** in
accordance with the terms and conditions (including
appropriate *** of a license agreement mutually acceptable
to the parties. With respect to *** Cytel grants to Searle
***
(b) If by the end of the Exclusivity Period, the parties have
not agreed on the terms and conditions of such license
agreement, then, except as otherwise provided in this
subsection (b) *** to obtain *** on the same terms and
conditions as contained in *** Cytel shall provide a copy
of *** The rights granted in this subsection (b) shall not
apply in
CONFIDENTIAL TREATMENT REQUESTED
<PAGE> 3
Cytel Corporation
September 5, 1997
Page 3
the event Searle does not execute definitive agreements due to
the reasons stated in Section III.1.
3. Exclusivity. Subject to the completion of the equity investment
under Section I.A.1. beginning *** and continuing *** (the
"Exclusivity Period"), Cytel shall not directly or indirectly
*** During the Exclusivity Period, Searle and Cytel shall
negotiate in good faith the definitive agreements contemplated
hereunder.
B. Phase II - Equity Investment.
Upon execution of the definitive agreements contemplated hereunder,
Searle will purchase *** of the common stock of Epimmune Entity (as
defined in Section I.D.9), for the purpose of funding the Epimmune
Entity; provided, however, *** In such event, *** Such *** (a) *** at a
time and price to be agreed, or (b) *** or (c) *** For the avoidance of
doubt, *** The per share purchase price of the common stock of Epimmune
shall be agreed by the parties based on ***
CONFIDENTIAL TREATMENT REQUESTED
<PAGE> 4
Cytel Corporation
September 5, 1997
Page 4
*** first set forth above in this Section B ***
C. Phase III - Equity Investment.
Not later than *** Searle will purchase *** of the common stock of
Epimmune Entity (as defined in Section I.D.9), for the purpose of ***
provided, however, *** In such event, *** Such *** (a) *** at a time and
price to be agreed, or (b) *** or (c) *** For the avoidance of doubt,
*** The per share purchase price of the common stock of Epimmune shall
be agreed by the parties based on ***
D. Related Covenants
1. License Rights. Cytel will grant to Searle *** to make, have
made, use and sell pharmaceutical cancer therapy products *** in
accordance with the terms and conditions (including appropriate
*** of a license agreement mutually acceptable to the parties.
2. *** to be
CONFIDENTIAL TREATMENT REQUESTED
<PAGE> 5
Cytel Corporation
September 5, 1997
Page 5
agreed upon by the parties in the definitive agreements
contemplated hereunder. In addition, in the event ***
3. ***
4. *** promptly following execution of the definitive agreements
contemplated hereunder.
5. Development of Products.
(a) The parties will collaborate and agree on a development
plan for the products licensed pursuant to paragraphs
I.A.2. and I.D.1. *** (the "Products"). The pre-clinical
and early clinical development of the Products shall be the
responsibility of Cytel. Searle shall *** as mutually
agreed by the parties.
(b) The pre-clinical and clinical development of the Products
shall be managed by a Joint Management Committee composed
of an equal number of representatives from each party. The
Joint Management Committee shall approve and oversee
implementation of the development plans for the Products.
If the Joint Management Committee is unable to reach
consensus on any issue for which it has responsibility ***
CONFIDENTIAL TREATMENT REQUESTED
<PAGE> 6
Cytel Corporation
September 5, 1997
Page 6
(c) In connection with the license agreements referred to in
paragraphs I.A.2. and I.D.1 *** the parties will negotiate
*** referred to in this paragraph I.D.5. *** The
circumstances constituting *** shall be agreed upon in the
definitive agreements.
6. Provision of Services. Cytel and Searle shall enter into an
agreement pursuant to which Searle will provide services for ***
pursuant to paragraphs I.A.2., I.D.1 *** Searle will provide
such services *** to be agreed by the parties.
7. Key Employees. If, in the course of conducting its due diligence
investigation of Cytel, Searle determines any Cytel employees
are critical to the development of the Products, Searle and
Cytel shall discuss reasonable methods for securing the
employment of such employees.
8. Preemptive Rights. Any purchase by Searle, as contemplated by
this offer letter, of the common stock of Cytel *** shall be
accompanied by the grant to Searle of preemptive rights to be
agreed by the parties.
9. Epimmune Entity. Cytel will undertake to form a separate entity
for its Epimmune unit ("Epimmune Entity"), contribute its assets
and liabilities relating to the Epimmune unit and transfer
appropriate personnel necessary to continue the operations of
the Epimmune unit. In addition, Cytel shall ***
II. TIMING. WE UNDERSTAND THAT CYTEL HAS A STRONG INTEREST IN CONCLUDING A
TRANSACTION OF THIS NATURE AS EXPEDITIOUSLY AS POSSIBLE. WE BELIEVE THAT
SEARLE IS A PREFERRED PARTNER IN THIS
CONFIDENTIAL TREATMENT REQUESTED
<PAGE> 7
Cytel Corporation
September 5, 1997
Page 7
REGARD. WE ARE COMMITTED TO A SPEEDY TRANSACTION CLOSE. INDEED, WITH THE
COOPERATION OF CYTEL, OUR AIM IS TO CLOSE THE COMPLETE TRANSACTION
CONTEMPLATED IN SECTIONS I.B.I.C. AND I.D. AS SOON AS POSSIBLE AFTER ***
III. CONDITIONS OF OFFER. Searle's offer and the consummation of the
transactions contemplated in Sections I.B., I.C. and I.D hereunder are
subject to the following terms and conditions:
1. obtaining all necessary corporate authority to conclude the
transactions contemplated hereunder;
2. completion of and satisfaction with *** as deemed necessary by
Searle including but not limited to *** Cytel warrants it will
disclose all such information;
3. execution of mutually agreed upon definitive agreements
detailing the terms of the transactions contemplated in Sections
I.B, I.C. and I.D. hereunder and containing such other
representations and warranties, indemnities, covenants,
conditions and provisions customarily contained in agreements
for transactions of similar nature and size as the transactions
contemplated hereunder;
4. the expiration, without any adverse governmental action, of any
applicable waiting periods under the Hart-Scott-Rodino Antitrust
Improvements Act of 1976;
5. receipt of Cytel's written acceptance referred to in paragraph
I.A.l.(c).
Nothing in this offer shall be construed in any way or for any reason
to obligate Searle to proceed with Phase II and/or Phase III. If
Searle decides not to proceed with Phase II and/or III, Searle shall
not be liable to Cytel in any amount and/or for any reason based on
this offer. This offer be amended only in writing signed by both
parties.
CONFIDENTIAL TREATMENT REQUESTED
<PAGE> 8
Cytel Corporation
September 5, 1997
Page 8
IV. MISCELLANEOUS. Except with respect to the investment contemplated in
Section I.A.1, this offer does not contain all matters upon which
definitive agreements must be reached and is expressly conditioned upon
Searle and Cytel entering into mutually satisfactory definitive
agreements, in form and substance satisfactory to their respective
counsel. Except with respect to the investment contemplated in Section
I.A.1, nothing contained in this offer letter shall obligate Searle to
proceed with the transactions contemplated hereunder if all of the
conditions listed in Section III of this letter are not met.
Cytel and Searle will keep this offer letter, its attachments and the
negotiations relating to this transaction confidential and will not
disclose (except as required by law) the terms of the offer, the
definitive agreements or the negotiations between the parties to any
third party without the express written consent of the other.
Searle acknowledges that Cytel will be obligated to announce the
acceptance of this offer, the equity investment completed under Section
I2A.1 and the scope of the transaction contemplated hereunder, excluding
specific terms and conditions. Such announcement will be agreed to by
the parties and issued immediately upon acceptance of this offer.
[The remainder of this page is left blank intentionally.]
<PAGE> 9
Cytel Corporation
September 5, 1997
Page 8
If the foregoing offer is acceptable to Cytel, please acknowledge your
acceptance of the offer and provisions set forth above by signing this letter in
duplicate below and returning one original to Searle no later than 5:00 p.m.,
Central Standard Time on September 5, 1997. This offer expires as of that date
and time if it is not accepted in the manner provided herein.
Searle is committed to forging an alliance with Cytel that is beneficial to both
parties and we are, therefore, willing to work with Cytel to reach a transaction
structure which meets both our business objectives. If you have any questions
about this offer or need further clarification of any item, please contact ***
Sincerely, Accepted and Agreed:
G.D. Searle & Co. CYTEL CORPORATION
By: /s/ Richard U. De Schutter By: /s/ Virgil Thompson
----------------------------- ------------------------------
Richard U. De Schutter
Chief Executive Officer Title: President & CEO
--------------------------
Date: September 5, 1997
--------------------------
cc: Deborah A. Schueren
V.P. Finance & CFO
<PAGE> 1
EXHIBIT 10.53
STOCK PURCHASE AGREEMENT
THIS STOCK PURCHASE AGREEMENT (this "Agreement") is made as of September
18, 1997 (the "Effective Date"), by and between CYTEL CORPORATION (the
"Company"), and G.D. SEARLE & CO. (the "Investor").
RECITALS
WHEREAS, the Company and the Investor have entered into that certain
letter of intent dated September 5, 1997 (the "Letter of Intent") and, to the
extent provided therein, have agreed to the transactions and matters described
therein; and
WHEREAS, pursuant to the Letter of Intent, the Investor agreed to purchase
from the Company shares of the Company's Common Stock on the terms and subject
to the conditions set forth in this Agreement.
NOW, THEREFORE, in consideration of the foregoing recitals and the mutual
covenants and agreements contained herein, the parties hereto, intending to be
legally bound, do hereby agree as follows:
AGREEMENT
1. DEFINITIONS
Capitalized terms used but not otherwise defined herein shall have the
meanings given such terms in the Letter of Intent.
2. PURCHASE AND SALE OF SHARES
2.1 PURCHASE AND SALE OF SHARES. Subject to the terms and conditions
hereof, at the Closing (as defined below), the Investor shall purchase from the
Company, and the Company shall issue and sell to the Investor, 2,000,000 shares
of Common Stock of the Company, at a per share purchase price equal to US$2.50,
for an aggregate purchase price of US$5,000,000, subject to adjustment as set
forth in Section 2.2 below (such shares, together with any shares issued
pursuant to the adjustment provided by Section 2.2, collectively, the "Shares").
<PAGE> 2
2.2 ADJUSTMENTS TO NUMBER OF SHARES.
(a) If the Company fails to sell shares of Series A Convertible
Preferred Stock of the Company, having an aggregate purchase price of not less
than US$7,000,000, to third party investors in the private placement (the
"Private Placement") on substantially the terms and conditions contemplated by
the Company's Confidential Private Placement Memorandum dated July 8, 1997 (the
"Private Placement Memorandum") on or before December 31, 1997, then and in such
event the Company shall issue to the Investor, within five (5) business days
after such date, at no additional consideration, 222,222 additional shares of
Common Stock of the Company.
(b) If the Company sells shares of Series A Convertible Preferred
Stock of the Company, having an aggregate purchase price of not less than
US$7,000,000, to third party investors in the Private Placement on or before
December 31, 1997 at a per share purchase price of less than US$2.00, then and
in such event the Company shall issue to the Investor, within five (5) business
days after the date of the closing of the Private Placement, that number of
additional shares of Common Stock of the Company so that the weighted average
purchase price per share of the shares of Common Stock of the Company issued to
the Investor pursuant to this Article 2 after giving effect to such additional
issuance equals the greater of (i) US$2.25 per share, or (ii) a per share price
equal to US$0.50 plus the per share purchase price at which shares of the Series
A Convertible Preferred Stock of the Company are sold to third party investors
in the Private Placement (but in no event to exceed $2.50 per share).
2.3 FRACTIONAL SHARES. The number of shares of Common Stock which the
Investor shall purchase pursuant to this Section 2 shall be equal to the
aggregate purchase price to be paid for such shares on the applicable purchase
date divided by the applicable per share price; provided, however, that the
Company shall issue no fractional share, and the Investor shall pay the
aggregate purchase price less an amount equal to the per share price multiplied
by such fractional share.
3. CLOSING DATE; DELIVERY.
3.1 CLOSING. Subject to the terms of Section 6, the closing of the sale and
purchase of the Shares pursuant to Section 2.1 above (the "Closing") shall be
held at 10:00 a.m. (Pacific Time) on the Effective Date, at the offices of the
Company, 3525 John Hopkins Court, San Diego, California, or at such time and
place as the Company and the Investor may agree.
3.2 DELIVERY. At the Closing, subject to the terms and conditions hereof,
the Company shall deliver to the Investor a stock certificate, registered in the
name of the Investor, representing the Shares purchased pursuant to Section 2.1
above and dated as of the Closing against payment of the purchase price therefor
by wire transfer, unless other
-2-
<PAGE> 3
means of payment shall have been agreed upon by the Company and the Investor.
4. REPRESENTATIONS AND WARRANTIES OF THE COMPANY
The Company hereby makes the following representations and warranties to
the Investor, except as set forth in the Schedule of Exceptions attached hereto
as Exhibit A:
4.1 ORGANIZATION, GOOD STANDING AND QUALIFICATION. The Company is a
corporation duly organized, validly existing and in good standing under the laws
of the State of Delaware and has all requisite corporate power and authority to
carry on its business. The Company is duly qualified to transact business and is
in good standing in each jurisdiction in which the failure so to qualify would
have a material adverse effect on its business or properties.
4.2 AUTHORIZATION; DUE EXECUTION. The Company has the requisite corporate
power and authority to enter into this Agreement and to perform its obligations
under the terms of this Agreement and, at the Closing, will have the requisite
corporate power to sell the Shares. All corporate action on the part of the
Company, its officers, directors and stockholders necessary for the
authorization, execution and delivery of this Agreement has been taken. This
Agreement has been duly authorized, executed and delivered by the Company, and,
upon due execution and delivery by the Investor, this Agreement will be a valid
and binding agreement of the Company, enforceable in accordance with its terms,
except as enforceability may be limited by bankruptcy, insolvency,
reorganization, moratorium or similar laws affecting creditors' rights generally
or by equitable principles.
4.3 CAPITALIZATION. The authorized capital stock of the Company consists of
50,000,000 shares of Common Stock, par value $.01, and 10,000,000 shares of
Preferred Stock, par value $.01. As of September 12, 1997, there were 25,214,886
shares of Common Stock and no shares of Preferred Stock issued and outstanding.
Other than (a) options to purchase 4,055,745 shares of Common Stock issued, and
751,651 shares of Common Stock available for future option grants, to certain
employees, officers, directors, consultants and advisors of the Company, (b)
47,666 shares of Common Stock to be issued under the Company's Employee Stock
Purchase Plan, (c) warrants to purchase 200,000 shares of Common Stock issued to
a certain investor, (d) those shares of Common Stock to be issued under the
Company's Rights Agreement, and (e) as otherwise set forth in the Letter of
Intent, there are no subscriptions, options, warrants, rights or agreements
(contingent or otherwise), including without limitation, conversion rights,
preemptive rights, rights of first refusal or other rights or agreements,
providing for the issuance by the Company of Common Stock or other equity
securities of the Company. The Shares to be acquired by the Investor pursuant to
Section 2.1 above will constitute (i)
-3-
<PAGE> 4
approximately 7.35% of the outstanding shares of Common Stock of the Company on
an undiluted basis, and (ii) approximately 6.4% of the outstanding Common Stock
of the Company on a fully diluted basis, assuming exercise of all outstanding
rights, warrants and options to acquire Common Stock.
4.4 VALID ISSUANCE OF SHARES. The Shares when issued, sold and delivered in
accordance with the terms hereof for the consideration set forth herein, will be
duly and validly authorized and issued, fully paid and nonassessable and, based
in part upon the representations of the Investor in this Agreement, will be
issued in compliance with all applicable federal and state securities laws.
4.5 GOVERNMENTAL CONSENTS. No consent, approval, order or authorization of,
or registration, qualification, designation, declaration or filing with, any
federal, state, local or provincial governmental authority on the part of the
Company is required in connection with the consummation of the transactions
contemplated by this Agreement, except for notices required or permitted to be
filed with certain state and federal securities commissions after the Closing,
which notices will be filed on a timely basis.
4.6 SEC FILINGS. The Company has timely filed all reports, registration
statements and other documents required to be filed by it (the "SEC Filings")
under the Securities Act of 1933, as amended, and the rules and regulations
promulgated thereunder (the "Securities Act"), and the Securities Exchange Act
of 1934, as amended, and the rules and regulations promulgated thereunder (the
"Exchange Act"). The SEC Filings were prepared in accordance and complied in all
material respects with the applicable requirements of the Securities Act or the
Exchange Act, as the case may be. None of such forms, reports and statements,
including, without limitation, any financial statements, exhibits and schedules
included therein and documents incorporated therein by reference, at the time
filed, declared effective or mailed, as the case may be, contained an untrue
statement of a material fact or omitted to state a material fact required to be
stated therein or necessary in order to make the statements therein, in light of
the circumstances under which they were made, not misleading. Except to the
extent information contained in any of the SEC Filings has been revised,
corrected or superseded by a later filing of any such form, report or document,
none of the SEC Filings currently contains an untrue statement of a material
fact or omits to state a material fact required to be stated therein or
necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading. Since June 30, 1997, (i) there has
been no material adverse change in the condition, financial or otherwise, of the
Company and its subsidiaries considered as a whole, or in the business,
operations, or prospects of the Company and its subsidiaries considered as a
whole, whether or not arising in the ordinary course of business, and (ii) there
has been no dividend or distribution of any kind declared, paid or
-4-
<PAGE> 5
made by the Company on any class of its capital stock.
4.7 NO CONFLICT. The execution, delivery and performance by the Company of
this Agreement do not and will not violate any provision of the Company's
Certificate of Incorporation or By-laws, any provision of any order, writ,
judgment, injunction, decree, determination or award to which the Company is a
party or by which it is bound, or to the Company's knowledge, any law, rule or
regulation (including, without limitation, the rules and regulations of the
Securities and Exchange Commission (the "SEC") or any regulatory commission of
any jurisdiction) currently in effect having applicability to the Company.
4.8 ABSENCE OF LITIGATION. Except as disclosed in the SEC Filings, there is
no action, suit, proceeding or investigation (including any such matter related
to the Company's intellectual property) pending or currently threatened against
the Company or its properties before any court or governmental agency, which
would, singly or in the aggregate, have a material adverse effect on the
Company's business, operations or assets, taken as a whole (nor, to the best of
the Company's knowledge, is there any basis therefor). There is no action, suit,
proceeding or investigation which the Company currently intends to initiate.
4.9 CONFIDENTIALITY. The Company hereby represents, warrants and covenants
that it shall maintain in confidence, and shall not use or disclose without
prior written consent of the Investor, the terms of this Agreement and any
information identified in writing as confidential that is furnished to it by the
Investor in connection with this Agreement. This obligation of confidentiality
shall not apply, however, to any information (a) in the public domain through no
unauthorized act or failure to act by the Company, (b) lawfully disclosed to the
Company by a third party who possessed such information without any obligation
of confidentiality, (c) lawfully developed by the Company independent of any
disclosure by the Company as supported by the Investor's written records, or (d)
required to be disclosed pursuant to applicable law, regulation or order or
requirement of a court, administrative agency or other government body
(including the securities laws of any applicable jurisdiction). The Company
further covenants that it shall return to the Investor all tangible materials
containing such information upon request by the Investor. The Company and the
Investor acknowledge and agree that the Company will be required to disclose the
issuance of the Shares contemplated by this Agreement pursuant to applicable
securities laws and regulations.
5. REPRESENTATIONS AND WARRANTIES OF THE INVESTOR
The Investor hereby makes the following representations and warranties to
the Company as of the Effective Date and the Closing:
-5-
<PAGE> 6
5.1 AUTHORIZATION; DUE EXECUTION. The Investor has the requisite corporate
power and authority to enter into this Agreement and to perform its obligations
under the terms of this Agreement and, at the Closing, will have the requisite
corporate power to purchase the Shares. All corporate action on the part of the
Investor, its officers, directors and stockholders necessary for the
authorization, execution and delivery of this Agreement has been taken. This
Agreement has been duly authorized, executed and delivered by the Investor, and,
upon due execution and delivery by the Company, this Agreement will be a valid
and binding agreement of the Investor, enforceable in accordance with its terms,
except as enforceability may be limited by bankruptcy, insolvency,
reorganization, moratorium or similar laws affecting creditors' rights generally
or by equitable principles.
5.2 PURCHASE ENTIRELY FOR OWN ACCOUNT. This Agreement is made with the
Investor in reliance upon such Investor's representation to the Company, which
by such Investor's execution of this Agreement such Investor confirms, that the
Shares to be purchased by such Investor will be acquired for investment for such
Investor's own account, not as a nominee or agent, and not with a view to the
resale or distribution of any part thereof, and that such Investor has no
present intention of selling, granting any participation in, or otherwise
distributing the same (subject to the disposition of the Investor's property
being at all times within its control). By executing this Agreement, the
Investor further represents that such Investor does not have any contract,
undertaking, agreement or arrangement with any person to sell, transfer or grant
participation to such person or to any third person, with respect to any of the
Shares.
5.3 DISCLOSURE OF INFORMATION. The Investor has received all the
information that it has requested and that it considers necessary or appropriate
for deciding whether to enter into this Agreement and to purchase the Shares.
The Investor further represents that it has had an opportunity to ask questions
and receive answers from the Company regarding the terms and conditions of the
offering of the Shares.
5.4 INVESTMENT EXPERIENCE. The Investor is an investor in securities of
companies in the development stage and acknowledges that it is able to fend for
itself, can bear the economic risk of its investment and has such knowledge and
experience in financial or business matters that it is capable of evaluating the
merits and risks of the investment in the Shares. The Investor also represents
it has not been organized solely for the purpose of acquiring the Shares.
5.5 ACCREDITED INVESTOR. The Investor is an "accredited investor" as such
term is defined in Rule 501 of the General Rules and Regulations prescribed by
the SEC pursuant to the Securities Act.
-6-
<PAGE> 7
5.6 RESTRICTED SECURITIES. The Investor understands that (a) the Shares
have not been, registered under the Securities Act by reason of a specific
exemption therefrom, that such securities must be held by it indefinitely and
that the Investor must, therefore, bear the economic risk of such investment
indefinitely, unless in each case a subsequent disposition thereof is registered
under the Securities Act or is exempt from such registration; (b) each
certificate representing the Shares will be endorsed with the following legend:
THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED
IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES
UNDER SAID ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT
SUCH REGISTRATION IS NOT REQUIRED.
and (c) the Company will instruct any transfer agent not to register the
transfer of the Shares (or any portion thereof) unless the conditions specified
in the foregoing legends are satisfied, until such time as a transfer is made,
pursuant to the terms of this Agreement, and in compliance with Rule 144 or
pursuant to a registration statement or, if the opinion of counsel referred to
above is to the further effect that such legend is not required in order to
establish compliance with any provisions of the Securities Act or this
Agreement.
5.7 CONFIDENTIALITY. The Investor hereby represents, warrants and covenants
that it shall maintain in confidence, and shall not use or disclose without
prior written consent of the Company, the terms of this Agreement and any
information identified in writing as confidential that is furnished to it by the
Company in connection with this Agreement. This obligation of confidentiality
shall not apply, however, to any information (a) in the public domain through no
unauthorized act or failure to act by the Investor, (b) lawfully disclosed to
such Investor by a third party who possessed such information without any
obligation of confidentiality, (c) lawfully developed by such Investor
independent of any disclosure by the Company as supported by the Investor's
written records, or (d) required to be disclosed pursuant to applicable law,
regulation or order or requirement of a court, administrative agency or other
government body (including the securities laws of any applicable jurisdiction).
The Investor further covenants that it shall return to the Company all tangible
materials containing such information upon request by the Company. The Company
and the Investor acknowledge and agree that the Investor will be required to
disclose its investment in the Company and the terms of this Agreement pursuant
to filing of a Form 13D with the SEC under the Exchange Act.
-7-
<PAGE> 8
6. CONDITIONS OF THE INVESTOR'S OBLIGATIONS
The obligations of the Investor under this Agreement are subject to the
fulfillment on or before the Closing of each of the following conditions, any of
which may be waived by the Investor (and which conditions shall be deemed to
have been fulfilled or waived upon the occurrence of the Closing):
6.1 REPRESENTATIONS AND WARRANTIES. The representations and warranties of
the Company contained in Section 4 shall be true and correct in all material
respects on and as of the Closing with the same effect as though such
representations and warranties had been made on and as of said date.
6.2 PERFORMANCE. The Company shall have performed and complied with all
agreements, obligations and conditions in this Agreement, if any, that are
required to be performed or complied with by it on or before the Closing.
6.3 DELIVERY OF SHARES. The Company shall have tendered delivery of the
Shares specified in Section 2.1 at the Closing.
6.4 LEGAL OPINION. An opinion of counsel to the Company in the form
attached hereto as Exhibit B shall have been delivered to the Investor at the
Closing.
6.5 PROCEEDINGS AND DOCUMENTS. All corporate and other proceedings in
connection with the transactions contemplated at the Closing and all documents
incident thereto shall be reasonably satisfactory in form and substance to the
Investor, and it shall have received all such counterpart original and certified
or other copies of such documents as it may reasonably request.
7. CONDITIONS OF THE COMPANY'S OBLIGATIONS
The obligations of the Company under this Agreement are subject to the
fulfillment on or before the Closing of each of the following conditions by such
Investor, any of which may be waived by the Company (and which conditions shall
be deemed to have been fulfilled or waived upon the occurrence of the Closing):
7.1 REPRESENTATIONS AND WARRANTIES. The representations and warranties of
the Investor contained in Section 5 hereof shall be true and correct in all
material respects on and as of the Closing with the same effect as though such
representations and warranties had been made on and as of said dates.
-8-
<PAGE> 9
7.2 PERFORMANCE. The Investor shall have performed and complied with all
agreements, obligations and conditions in this Agreement, if any, that are
required to be performed or complied with by it on or before the Closing.
7.3 PAYMENT OF PURCHASE PRICE. The Investor shall have tendered delivery of
the purchase price for the Shares specified in Section 2.1 at the Closing.
7.4 PROCEEDINGS AND DOCUMENTS. All corporate and other proceedings in
connection with the transactions contemplated at the Closing and all documents
incident thereto shall be reasonably satisfactory in form and substance to the
Company, and it shall have received all such counterpart original and certified
or other copies of such documents as it may reasonably request.
8. COVENANTS
8.1 DELIVERY OF FINANCIAL STATEMENTS. So long as the Investor (or any
transferee pursuant to Section 11.5) holds the Shares, the Company shall deliver
to the Investor (or any such transferee pursuant to Section 11.5) copies of its
Forms 10-K and 10-Q as filed with the SEC, and other public announcements and
releases made by the Company.
8.2 STANDSTILL AGREEMENT. The Investor hereby covenants and agrees that,
prior to December 31, 2000, it will not, nor will it permit any of its
affiliates (including parents, subsidiaries or other related entities) to,
purchase or otherwise acquire or offer or agree to acquire, directly or
indirectly, beneficial ownership of any additional equity securities of the
Company (or rights or options to purchase such securities) after the Closing in
an amount that would cause the Investor to own, on a fully diluted basis, more
than 19% of the outstanding shares of Common Stock of the Company, without the
prior written consent of the Company; provided, however, that this clause shall
not apply to any securities issued with respect to the Shares pursuant to a
stock split, stock dividend, recapitalization or reclassification approved by a
disinterested majority of the Company's Board of Directors.
8.3 "MARKET STAND-OFF" AGREEMENT. The Investor hereby agrees that during
the period specified by the Company and an underwriter of Common Stock or other
securities of the Company following the effective date of a Registration
Statement of the Company filed under the Securities Act (which period shall not
exceed 120 days), to the extent requested by the Company and such underwriter,
it shall not, nor will it permit any of its affiliates (including parents,
subsidiaries or other related entities) to, directly or indirectly sell,
contract to sell (including, without limitation, any short sale), grant any
option to purchase or otherwise transfer or dispose of any securities of the
Company held
-9-
<PAGE> 10
by any of them during such period; provided, however, that any such request will
be made no more frequently than once every eight (8) months.
8.4 REPORTING PERSON STATUS. For such period as the Investor or any
transferee pursuant to Section 11.5 owns all or part of the Shares, the Company
shall maintain its status as a reporting company under the Exchange Act and the
registration of its Common Stock pursuant to Section 12 of such Act and shall
timely file all forms, reports and documents required to be filed under the
Exchange Act, so as to ensure satisfaction of the condition contained in Rule
144(c) under the Securities Act relating to availability of adequate current
public information relating to the Company.
8.5 USE OF PROCEEDS. The Company agrees to use the purchase price of the
Shares paid pursuant to Section 2 hereof for the purpose of funding its Epimmune
unit.
8.6 LICENSE RIGHTS. Without altering or affecting the Letter of
Intent or its terms and conditions, the Company and the Investor hereby
agree to, accept, ratify and confirm the terms, conditions and agreements
contained in Section I.A.2(b) of the Letter of Intent, which are incorporated
herein by reference.
9. RIGHT OF FIRST REFUSAL
9.1 SUBSEQUENT OFFERINGS. The Investor shall have a right of first refusal
to purchase its pro rata share of all Equity Securities, as defined below, that
the Company may, from time to time, propose to sell and issue after the date of
this Agreement, other than the Equity Securities excluded by Section 9.6 hereof.
The Investor's pro rata share is equal to the ratio of (a) the number of Shares
purchased pursuant to Article 2, plus the number of shares of Common Stock (and
the number of shares of Common Stock issued or issuable upon the conversion of
any Equity Securities) previously purchased pursuant to this Article 9, held by
the Investor or any transferee pursuant to Section 11.5, to (b) the total number
of shares of the Company's outstanding Common Stock (including all shares of
Common Stock issued or issuable upon the conversion of any Equity Securities or
upon exercise of any outstanding warrants or options) immediately prior to the
issuance of the Equity Securities. The term "Equity Securities" shall mean (i)
any Common Stock, Preferred Stock or other security of the Company, (ii) any
security convertible, with or without consideration, into any Common Stock,
Preferred Stock or other security (including any option, warrant or other right
to purchase such a convertible security), (iii) any security carrying any
warrant or right to subscribe to or purchase any Common Stock, Preferred Stock
or other security, or (iv) any such warrant or right.
9.2 EXERCISE OF RIGHT OF FIRST REFUSAL. If the Company proposes to
issue any
-10-
<PAGE> 11
Equity Securities, it shall give the Investor written notice of its intention,
describing the Equity Securities, the price and the terms and conditions upon
which the Company proposes to issue the same. The Investor shall have forty five
(45) days from the giving of such notice to agree to purchase its pro rata share
of the Equity Securities for the price and upon the terms and conditions
specified in the notice by giving written notice to the Company and stating
therein the quantity of Equity Securities to be purchased; provided, however, if
the Company reasonably requests in the Company's original notice that the
Investor respond within thirty (30) days (due to timing considerations relating
to the closing of the issuance of such Equity Securities), then the Investor
shall be required to respond to such notice within thirty (30) days.
Notwithstanding the foregoing, the Company shall not be required to offer or
sell such Equity Securities to the Investor if doing so would cause the Company
to be in violation of applicable federal securities laws by virtue of such offer
or sale; provided, however, the Company agrees to use its reasonable best
efforts to take whatever action may be necessary or appropriate to comply with
applicable federal securities laws in connection with such offer or sale.
9.3 ISSUANCE OF EQUITY SECURITIES TO OTHER PERSONS. If the Investor fails
to exercise in full the right of first refusal, the Company shall have ninety
(90) days thereafter to sell the Equity Securities in respect of which the
Investor's right was not exercised, at a price and upon general terms and
conditions materially no more favorable to the purchasers thereof than specified
in the Company's notice to the Investor pursuant to Section 9.2 hereof. If the
Company has not sold such Equity Securities within ninety (90) days of the
notice provided pursuant to Section 9.2, the Company shall not thereafter issue
or sell any Equity Securities, without first offering such securities to the
Investor in the manner provided above.
9.4 TERMINATION OF RIGHT OF FIRST REFUSAL. The right of first refusal
established by this Section 9 shall terminate on the first to occur of (a)
September 17, 2002, or (b) the first date on which the Investor sells, assigns
or otherwise transfers any of the Shares, excluding, however, transfers pursuant
to Section 11.5.
9.5 NO TRANSFER OF RIGHT OF FIRST REFUSAL. The right of first refusal
established by this Section 9 may not be assigned or transferred, except as
otherwise provided in Section 11.5.
9.6 EXCLUDED SECURITIES. The right of first refusal established by Sections
9.1, 9.2 and 9.3 shall have no application to any of the following Equity
Securities:
(a) shares of Common Stock (and/or options, warrants or other Common
Stock purchase rights issued pursuant to such options, warrants or other rights)
issued or
-11-
<PAGE> 12
to be issued to employees, officers or directors of, or consultants or advisors
to the Company or any subsidiary, pursuant to stock purchase or stock option
plans or other compensatory arrangements that are approved by the Board of
Directors;
(b) stock issued pursuant to any rights, agreements, options or
warrants outstanding as of the date of this Agreement, and stock issued pursuant
to any rights, agreements, options or warrants granted after the date of this
Agreement provided that the right of first refusal established by this Section 9
did not apply to the initial sale or grant by the Company of such rights,
agreements, options or warrants;
(c) any Equity Securities issued for consideration other than cash
pursuant to a merger, consolidation, acquisition or similar business combination
whereby the stockholders of the Company will own more than fifty percent (50%)
of the voting power of the combined entity;
(d) shares of Common Stock issued in connection with any stock split,
stock dividend or recapitalization by the Company;
(e) shares of Common Stock issued upon conversion of any Equity
Securities;
(f) any Equity Securities issued pursuant to any equipment leasing
arrangement; and
(g) shares of the Company's Common Stock or Preferred Stock issued in
connection with strategic transactions involving the Company and any third
party, including (i) joint ventures, manufacturing, marketing, corporate
partnering or distribution arrangements, or (ii) technology transfer, research
or development arrangements; provided that such strategic transactions and the
issuance of shares therein, has been approved by the Company's Board of
Directors.
Notwithstanding the foregoing, during the term of the right of first
refusal under this Article 9, if at any time or from time to time after the date
of this Agreement the Company issues, pursuant to one or more transactions
described in Sections 9.6 (a) through (g), shares of its Common Stock (whether a
new issuance of Common Stock, or Common Stock issued upon the exercise of an
Equity Security, option, warrant or conversion or exchange right or other
similar right), and if upon such issuance the number of Shares purchased
pursuant to Sections 2.1 and 2.2 hereof, plus the number of shares of Common
Stock (and the number of shares of Common Stock issued or issuable upon the
conversion of any Equity Securities) previously purchased pursuant to this
Article 9 (collectively, the
-12-
<PAGE> 13
"Investor Share Number"), in each case then held by the Investor or any
transferee pursuant to Section 11.5, is less than 95% of the Trigger Percentage
(as defined below) (the date of the consummation of each issuance of Common
Stock causing such occurrence being referred to herein as a "Trigger Date") as
of such Trigger Date, the Investor shall have the right, effective as of the
next February 28 or August 31 immediately following such Trigger Date (such date
being referred to herein as a "Semi-Annual Exercise Date"), except as otherwise
set forth in the first immediately following paragraph, to purchase from the
Company a number of shares of Common Stock (the "Percentage Purchase Right")
such that the sum of (a) the Investor Share Number, plus (b) the number of
shares to be purchased by the Investor pursuant to the Percentage Purchase Right
on such Semi-Annual Exercise Date, shall equal the Trigger Percentage as of such
Semi-Annual Exercise Date. The "Trigger Percentage" shall mean, as to any date,
7.35% subject to the following adjustments: In the case (i) the Company issues
Common Stock after the date of this Agreement pursuant to the exercise of any
option, warrant or conversion or exchange right outstanding as of the date of
this Agreement (collectively, "Later Share Issuances"), or (ii) the Investor
waives, or elects not to exercise, a right to purchase Common Stock or other
Equity Securities under this Article 9 (including Section 9.1 and this Section
9.6) (an "Unexercised Investor Right"), or (iii) the Company issues any Shares
to the Investor pursuant to Section 2.2, then the applicable Trigger Percentage,
as of the date of determination, shall be adjusted to a percentage which equates
to the quotient of (A) the Investor Share Number as of the date of determining
such Trigger Percentage, divided by (B) the sum of 27,214,886, plus (x) the
aggregate number of shares of Common Stock of the Company issued pursuant to
Later Shares Issuances as of the date of determining such Trigger Percentage,
plus (y) the aggregate number of shares of Common Stock of the Company issued in
transactions involving an Unexercised Investor Right as of the date of
determining such Trigger Percentage, plus (z) the number of Shares (if any)
issued pursuant to Section 2.2.
The Investor shall have the right to waive its Percentage Purchase Right
for any Semi-Annual Exercise Date by giving express written notice of such
waiver to the Company not less than thirty (30) trading days prior to such
Semi-Annual Exercise Date.
The price per share of Common Stock of the Company to be purchased by the
Investor pursuant to the Percentage Purchase Right shall be the fair market
value per share of the Common Stock of the Company as of the applicable
Semi-Annual Exercise Date, determined by averaging the per share closing prices
on the Nasdaq Stock Market of the Common Stock of the Company for the ten (10)
consecutive trading days immediately prior to such Semi-Annual Exercise Date
(the "Market Valuation"). To the extent that the Company has outstanding or
issues Equity Securities, options, warrants or purchase or subscription rights
which convert into or can be exchanged for shares of Common Stock,
-13-
<PAGE> 14
the parties agree that a Trigger Date shall not have occurred with respect to
such securities until such time as the Common Stock underlying such Equity
Securities, options, warrants, rights or other securities is issued.
If at any time or from time to time the Company issues additional shares
of Common Stock which gives rise to the occurrence of a Trigger Date, it shall
give the Investor written notice within ten (10) days after the next following
Semi-Annual Exercise Date, which notice shall include the number of shares of
Common Stock which are subject to the Percentage Purchase Right, the Market
Valuation of such shares and sufficient information in order to reasonably
substantiate the Market Valuation. Upon receipt of such notice, the Investor
shall have forty-five (45) days to give written notice to the Company that it
wishes to exercise its Percentage Purchase Right. The purchase and sale of
shares of Common Stock pursuant to exercise of the Percentage Purchase Right
shall occur within fifteen (15) days after such exercise pursuant to a stock
purchase agreement containing terms and conditions substantially the same as
those contained in this Agreement, with appropriate modifications to reflect the
terms of such purchase and sale as contemplated by this Section 9.6 and
appropriate updating of information, and excluding Sections 8.2, 8.3, 8.5 and
8.6. Notwithstanding the foregoing, the Company shall not be required to offer
or sell such shares of Common Stock to the Investor if doing so would cause the
Company to be in violation of applicable federal securities laws by virtue of
such offer and sale, provided that the Company agrees to use reasonable best
efforts to take whatever action may be necessary or appropriate to comply with
such federal securities laws.
Unless the Investor has timely and expressly waived its Percentage
Purchase Right for any Semi-Annual Exercise Date as set forth above, by giving
express written notice of such waiver to the Company not less than thirty (30)
trading days prior to such Semi-Annual Exercise Date, the Investor hereby agrees
that during the period of thirty (30) trading days prior to such Semi-Annual
Exercise Date, it shall not, and will not permit any of its affiliates
(including parents, subsidiaries or other related entities) to, directly or
indirectly sell, contract to sell (including, without limitation, any short
sale), grant any option to purchase or otherwise transfer or dispose of any
securities of the Company held by any of them during such period.
9.7 PRIVATE PLACEMENT. If the investors in the Private Placement are
granted rights of first refusal in the Private Placement on terms and conditions
which in the reasonable judgment of the Investor are more favorable to such
investors, taken as a whole, than the right of first refusal granted to the
Investor pursuant to this Article 9, taken as a whole, then and in such event
the Investor shall have the option, exercisable by written notice to the
Company, to deem the provisions of this Article 9 to be amended in
-14-
<PAGE> 15
their entirety (without further action by either party) to conform with the
terms and conditions of the right of first refusal granted to the investors in
the Private Placement; provided, however, in no event shall the right of first
refusal permit the Investor to purchase the pro rata share of the Equity
Securities of any such investor in the Private Placement or any other person if
such investor or other person fails to exercise its right of first refusal in
full.
9.8 FUTURE REVISIONS. The parties acknowledge and agree that, in connection
with the negotiation of the definitive agreements contemplated by the Letter of
Intent, mutually acceptable and appropriate revisions to the provisions of this
Article 9 will be necessary and appropriate in recognition of the increased
investment by the Investor in the Company and its subsidiaries.
10. INDEMNIFICATION
10.1 INDEMNIFICATION OF THE INVESTOR. The Company agrees to indemnify and
hold harmless the Investor and its permitted successors and assigns from and
against any and all (i) liabilities, losses, costs or damages ("Loss") and (ii)
reasonable attorneys' and accountants' fees and expenses, court costs and all
other reasonable out-of-pocket expenses ("Expense") incurred by the Investor or
its permitted successors and assigns arising from (A) any breach or failure to
perform by the Company of any of its covenants or agreements contained in this
Agreement; or (B) any breach of any warranty or the inaccuracy of any
representation of the Company contained in this Agreement.
10.2 NOTICE OF CLAIMS BY THE INVESTOR. If any person indemnified under
Section 10.1 hereof believes it has suffered or incurred any Loss or incurred
any Expense as to which it is entitled to indemnification under Section 10.1
hereof, such person shall so notify the Company promptly in writing describing
such Loss or Expense, the amount thereof, if known, and the method of
computation of such Loss or Expense, all with reasonable particularity and
containing a reference to the provisions of this Agreement, or any agreement or
instrument contemplated hereby, or any certificate delivered pursuant hereto or
thereto in respect of which such Loss or Expense shall have occurred; and if any
action at law or suit in equity is instituted by or against a third party with
respect to which any such indemnified person intends to claim any Loss or
Expense under Section 10.1, such indemnified person shall promptly notify the
indemnifying party of such action or suit; provided that failure to give such
notice shall not abrogate or diminish the Company's obligations under Section
10.1 if the Company has or receives timely actual knowledge of the existence of
any such claim by any other means or except to the extent such failure
prejudices the Company.
-15-
<PAGE> 16
10.3 INDEMNIFICATION OF THE COMPANY. The Investor agrees to indemnify and
hold harmless the Company and its permitted successors and assigns from and
against any and all Loss and Expense incurred by the Company and its permitted
successors and assigns arising from (i) any breach or failure to perform by the
Investor of any of its covenants or agreements contained in this Agreement; or
(ii) any breach of any warranty or the inaccuracy of any representation of the
Investor contained in this Agreement.
10.4 NOTICE OF CLAIMS BY THE COMPANY. If any person indemnified under
Section 10.3 believes that it has suffered or incurred any Loss or incurred any
Expense as to which it is entitled to indemnification under Section 10.3, such
person shall so notify the Investor or person responsible for such
indemnification promptly in writing describing such Loss or Expense, the amount
thereof, if known, and the method of computation of such Loss or Expense, all
with reasonable particularity and containing a reference to the provisions of
this Agreement, or any agreement or instrument contemplated hereby, or any
certificate delivered pursuant hereto or thereto in respect of which such Loss
or Expense shall have occurred; and if any action at law or suit in equity is
instituted by or against a third party with respect to which any such
indemnified party intends to claim any Loss or Expense under Section 10.3, such
indemnified party shall promptly notify the indemnifying party of such action or
suit; provided that failure to give such notice shall not abrogate or diminish
the Investor's obligations under Section 10.3 if the Investor has or receives
timely actual knowledge of the existence of any such claim by any other means or
except to the extent such failure prejudices the Investor.
10.5 THIRD PARTY CLAIMS. The indemnifying party shall have the right to
participate in, and, to the extent the it so desires, jointly with any other
indemnitor similarly noticed, to assume the defense of any third party claim,
demand, action or other proceeding with counsel selected by the indemnifying
party; provided, however, that the indemnified party shall have the right to
retain its own counsel, with the fees and expenses to be paid by the
indemnifying party, if representation of the indemnified party by the counsel
retained by the indemnifying party would be inappropriate due to actual or
potential differing interests between the indemnified party and any other party
represented by such counsel in such proceedings. So long as the indemnifying
party has received notice of any third party claim, demand, action or proceeding
for which any indemnified party intends to claim any Loss or Expense, and within
a reasonable period thereafter the indemnifying party has assumed the defense
thereof, the indemnity obligations under this Article 10 shall not apply to
amounts paid in settlement of such third party claim, demand, action or
proceeding if such settlement is effected without the consent of the
indemnifying party, which consent shall not be unreasonably withheld or delayed.
The indemnifying party may not settle or otherwise consent to an adverse
judgment in any such third party claim, demand, action or proceeding action that
diminishes the rights or interests of the
-16-
<PAGE> 17
indemnified party without the prior express written consent of the indemnified
party. The indemnified party, its employees and agents, shall cooperate
reasonably with the indemnifying party and its legal representatives in the
investigation of any third party claim, demand, action or proceeding covered by
this Article 10.
11. MISCELLANEOUS
11.1 SUCCESSORS AND ASSIGNS. The terms and conditions of this Agreement
shall inure to the benefit of and be binding upon the respective permitted
successors and assigns of the parties. Nothing in this Agreement, express or
implied, is intended to confer upon any party other than the parties hereto or
their respective permitted successors and assigns any rights, remedies,
obligations, or liabilities under or by reason of this Agreement, except as
expressly provided in this Agreement.
11.2 GOVERNING LAW. This Agreement shall be governed by and construed under
the laws of the State of California, as applied to contracts executed and
performed entirely within the State of California, without regard to conflicts
of laws rules.
11.3 COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.
11.4 TITLES AND SUBTITLES. The titles and subtitles used in this Agreement
are used for convenience only and are not to be considered in construing or
interpreting this Agreement.
11.5 ASSIGNMENT. This Agreement may not be assigned or otherwise
transferred, nor, except as expressly provided hereunder, may any right or
obligations hereunder be assigned or transferred, by either party without the
written consent of the other party; provided, however, that either the Company
or the Investor may, without such consent, assign this Agreement and its rights
and obligations hereunder (a) in connection with the transfer or sale of all or
substantially all of its business, if such assets include substantially all of
the assets relating to its performance of its respective obligations hereunder
or (b) in the event of its merger or consolidation with another company at any
time during the term of this Agreement. Any purported assignment in violation of
the preceding sentence shall be void. Any other permitted assignee shall also
assume all obligations of its assignor under this Agreement.
11.6 NOTICES. Any notice or report required or permitted to be given or
made under this Agreement by one of the parties hereto to the other shall be in
writing, delivered
-17-
<PAGE> 18
personally or by facsimile (and promptly confirmed by personal delivery or
courier) or courier, postage prepaid, addressed to such other party at its
address indicated below, or to such other address as the addressee shall have
last furnished in writing to the addressor and shall be effective upon receipt
by the addressee.
The Company: Cytel Corporation
3525 John Hopkins Court
San Diego, California 92121
Attention: President
Tel: (619) 552-3000
Fax: (619) 552-8801
The Investor: G.D. Searle & Co.
P.O. Box 5110
Chicago, Illinois 60680-5110
Attention: Vice President, Business Development
Tel: (847) 982-7000
Fax: (847) 470-1480
with a copy to: G.D. Searle & Co.
P.O. Box 5110
Chicago, Illinois 60680-5110
Attention: General Counsel
Tel: (847) 982-7000
Fax: (847) 967-2045
11.7 FINDER'S FEE. Each party represents that it neither is nor will be
obligated for any finders' fee or commission in connection with this
transaction. The Investor agrees to indemnify and hold harmless the Company from
any liability for any commission or compensation in the nature of a finders' fee
(and the costs and expenses of defending against such liability or asserted
liability) for which the Investor or any of its officers, partners, employees or
representatives is responsible. The Company agrees to indemnify and hold
harmless the Investor from any liability for any commission or compensation in
the nature of a finder's fee (and the costs and expenses of defending against
such liability or asserted liability) for which the Company or any of its
officers, employees or representatives is responsible.
11.8 EXPENSES. Irrespective of whether the Closing is effected, each party
shall bear its own costs with respect to the negotiation, execution, delivery
and performance of this Agreement.
-18-
<PAGE> 19
11.9 AMENDMENTS AND WAIVERS. Except as specified in this Section 11.9, any
term of this Agreement may be amended and the observance of any term of this
Agreement may be waived (either generally or in a particular instance and either
retroactively or prospectively) only with the written consent of the Company and
the Investor.
11.10 SEVERABILITY. If one or more provisions of this Agreement is held to
be unenforceable under applicable law, such provision shall be excluded from
this Agreement and the balance of this Agreement shall be interpreted as if such
provision were so excluded and shall be enforceable in accordance with its
terms.
11.11 ENTIRE AGREEMENT. This Agreement constitutes the entire agreement
between the parties hereto with regard to the subject matter hereof.
11.12 FURTHER ASSURANCES. Each party hereto agrees to do such further
actions and things, and to execute and deliver such additional agreements and
instruments, as either party may reasonably request of the other to effectuate
the transactions contemplated by this Agreement.
-19-
<PAGE> 20
IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first above written.
CYTEL CORPORATION
By: /s/ Deborah Schueren
------------------------------------
Title: V.P. and Chief Financial Officer
---------------------------------
G.D. SEARLE & CO.
By: /s/ Philip Needleman
------------------------------------
Title: President
---------------------------------
-20-
<TABLE> <S> <C>
<ARTICLE> 5
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> DEC-31-1997
<PERIOD-START> JAN-01-1997
<PERIOD-END> SEP-30-1997
<CASH> 4,832
<SECURITIES> 10,299
<RECEIVABLES> 0
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 16,761
<PP&E> 8,959
<DEPRECIATION> (7,398)
<TOTAL-ASSETS> 25,133
<CURRENT-LIABILITIES> 2,752
<BONDS> 0
<COMMON> 123,391
0
0
<OTHER-SE> (103,223)
<TOTAL-LIABILITY-AND-EQUITY> 25,133
<SALES> 0
<TOTAL-REVENUES> 3,881
<CGS> 0
<TOTAL-COSTS> 0
<OTHER-EXPENSES> 14,882
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 95
<INCOME-PRETAX> (10,386)
<INCOME-TAX> 0
<INCOME-CONTINUING> (10,386)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (10,386)
<EPS-PRIMARY> (0.41)
<EPS-DILUTED> (0.41)
</TABLE>
